Page last updated: 2024-12-05

flupenthixol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flupenthixol is a typical antipsychotic medication belonging to the thioxanthene class. It was first synthesized in the 1960s and is primarily used to treat schizophrenia and other psychotic disorders. Flupenthixol is a potent dopamine antagonist, meaning it blocks the action of dopamine, a neurotransmitter involved in mood, behavior, and cognition. Its antipsychotic effects are attributed to its ability to block dopamine receptors in the mesolimbic pathway, a brain region associated with reward and motivation. Flupenthixol is also known to have some sedative and anticholinergic effects. Flupenthixol is available in several forms, including tablets, capsules, injectable solutions, and long-acting depot injections. It is typically administered orally, but can also be given intravenously or intramuscularly. The long-acting formulation allows for a more sustained therapeutic effect, which can be beneficial for patients with schizophrenia who may have difficulty adhering to a daily medication regimen. Flupenthixol is often prescribed as a second-line treatment for schizophrenia, after other antipsychotics have been tried and found to be ineffective. It is also used to treat other psychotic disorders, such as bipolar disorder, and to manage agitation in patients with dementia. Flupenthixol is a relatively well-tolerated medication, but it can cause a variety of side effects, including extrapyramidal symptoms (EPS), such as tremors, muscle stiffness, and akathisia, as well as anticholinergic effects, such as dry mouth, blurred vision, and constipation. It is also important to note that flupenthixol can interact with other medications, including alcohol, so it is important to inform a doctor about all medications and supplements being taken before starting flupenthixol. Research on flupenthixol continues to investigate its efficacy and safety, as well as its potential for use in the treatment of other conditions. Flupenthixol is a valuable tool for the treatment of psychotic disorders, but it is important to use it carefully and under the guidance of a healthcare professional.'

Flupenthixol: A thioxanthene neuroleptic that, unlike CHLORPROMAZINE, is claimed to have CNS-activating properties. It is used in the treatment of psychoses although not in excited or manic patients. (From Martindale, The Extra Pharmacopoeia, 30th ed, p595) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flupenthixol : A thioxanthene derivative having a trifluoromethyl substituent at the 2-position and a 3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene group at the 10-position with undefined double bond stereochemistry. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cis-flupenthixol : A flupenthixol in which the double bond adopts a cis-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID17012
CHEMBL ID4743867
MeSH IDM0008640
PubMed CID5281881
CHEMBL ID54661
CHEBI ID10454
SCHEMBL ID34200
MeSH IDM0008640

Synonyms (104)

Synonym
2709-56-0
flupentixol
flupenthixol
PRESTWICK0_000340
PRESTWICK1_000340
SPBIO_002300
2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
DTXSID3058749
2-[4-[3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol
(ez)-2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
Q27164953
njmyodhxakyrhw-uhfffaoysa-n
CHEMBL4743867
BRD-K70487031-001-01-0
cis flupenthixol
gtpl948
BSPBIO_000379
BPBIO1_001183
PRESTWICK2_000340
LOPAC0_000528
PRESTWICK3_000340
BPBIO1_000417
cis-flupentixol
4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-1-piperazineethanol
1-piperazineethanol, 4-(3-(2-(trifluoromethyl)thioxanthen-9-ylidene)propyl)-
(z)-4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-1-piperazineethanol
1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-, (z)-
lc 44
siplarol
1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-
einecs 258-756-4
cis-flupenthixol
flupentixolum [inn-latin]
siplaril
fluxanxol
fluanxol
2-trifluoromethyl-9-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene)thioxanthene
4-(3-(2-(trifluoromethyl)thioxanthen-9-ylidene)propyl)-1-piperazineethanol
alpha-flupenthixol
(z)-4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)piperazine-1-ethanol
einecs 220-304-9
1-piperazineethanol, 4-[(3z)-3-[2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl]-
2-[4-[(3z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
cis(z)flupenthixol
53772-82-0
cis-(z)-flupenthixol
flupenthixole
DB00875
flupentixolo
NCGC00162179-03
D01044
flupentixol (inn)
depixol (tn)
NCGC00162179-02
BIOMOL-NT_000021
NCGC00162179-04
NCGC00162179-01
NCGC00162179-05
L000972
CHEMBL54661
lc-44
chebi:10454 ,
n-7009
NCGC00162179-06
unii-21hmq851is
flupentixol [inn:ban:dcf]
21hmq851is ,
dtxsid9046310 ,
cas-53772-82-0
tox21_112003
dtxcid7026310
CCG-204618
fluphenthixol
flurentixol
zuflupentixol
unii-fa0uyh6quo
fa0uyh6quo ,
z-flupenthixol
.alpha.-flupenthixol
4-((3z)-3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-1-piperazineethanol
flupentixol, (z)-
1-piperazineethanol, 4-((3z)-3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-
z-flupentixol
SCHEMBL34200
tox21_112003_1
NCGC00162179-08
bdbm79172
2-[4-[(3z)-3-[2-(trifluoromethyl)-9-thioxanthenylidene]propyl]-1-piperazinyl]ethanol;hydrochloride
cid_10140115
2-[4-[(3z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazino]ethanol;hydrochloride
2-trifluoromethyl-9-(3-(4-(.beta.-hydroxyethyl)-1-piperazinyl)propylidene)thioxanthene
2-(4-(3-[2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl)-1-piperazinyl)ethanol #
1-piperazineethanol, 4-[3-[2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl]-
2-trifluoromethyl-9-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propylidene]thioxanthene
W-107130
(z)-4-[3-[2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl]piperazine-1-ethanol
4-[3-[2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl]-1-piperazineethanol
(z)-2-(4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)piperazin-1-yl)ethanol
Q420350
(z)-flupentixol
SDCCGSBI-0050511.P002
NCGC00162179-12
EN300-21702589
2-(4-{3-[(9z)-2-(trifluoromethyl)-9h-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol

Research Excerpts

Overview

Flupenthixol decanoate is an established antipsychotic drug. It is well known for its mild antidepressant and anxiolytic activity.

ExcerptReferenceRelevance
"Flupenthixol is an antipsychotic drug with known mood-elevating properties. "( Association between flupenthixol treatment and emergence of manic symptoms.
Becker, D; Grinberg, Y; Mester, R; Weizman, A, 2002
)
2.08
"Flupenthixol decanoate is an established antipsychotic drug, which is well known for its mild antidepressant and anxiolytic activity as well as for its minimal sedation at low doses."( Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics.
Boening, J; Glaser, T; Lesch, OM; Weijers, HG; Wiesbeck, GA; Wodarz, N, 2003
)
1.27

Effects

Flupenthixol decanoate has also a pronounced antidepressive and anxiolytic effect which appears to be adequate enough for treating mild to moderately severe syndromes of depression. FlupenthIXol (FLX) has been shown to attenuate the discriminative stimulus effects of psychostimulants.

ExcerptReferenceRelevance
"Flupenthixol decanoate has also a pronounced antidepressive and anxiolytic effect which appears to be adequate enough for treating mild to moderately severe syndromes of depression."( Depression-inducing and antidepressive effects of neuroleptics. Experiences with flupenthixol and flupenthixol decanoate.
Pöldinger, W; Sieberns, S, 1983
)
1.21
"Flupenthixol (FLX) has the distinct advantage of being both a neuroleptic medication and a potential treatment for cocaine abuse."( Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
Collins, ED; Coomaraswammy, S; Evans, SM; Kleber, HD; Levin, FR; Regent, N, 1998
)
2.46
"Flupenthixol has been shown to attenuate the discriminative stimulus effects of psychostimulants, as well as their intake in animal models of drug abuse."( Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence.
De Vry, J; Soyka, M, 2000
)
2.47

Treatment

Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred. Pretreatment with flup tenthixol significantly reduced methylphenidate-induced increases in glucose utilization.

ExcerptReferenceRelevance
"Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred."( Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels.
Anghelescu, I; Benkert, O; Ewald-Gründer, S; Gründer, G; Hiemke, C; Hillert, A; Schlösser, R, 2002
)
1.04
"Flupenthixol pretreatment blocked many of the ethanol-induced increases in glucose utilization at the 0.25 g/kg dose, particularly in mesocorticolimbic and nigrostriatal structures."( II. Functional consequences of intragastrically administered ethanol in rats as measured by the 2-[14C]deoxyglucose method: the contribution of dopamine.
Porrino, LJ; Williams-Hemby, L, 1997
)
1.02
"Pretreatment with flupenthixol significantly reduced methylphenidate-induced increases in glucose utilization in structures of the mesocorticolimbic and nigrostriatal dopamine circuits."( II. Functional consequences of intragastrically administered ethanol in rats as measured by the 2-[14C]deoxyglucose method: the contribution of dopamine.
Porrino, LJ; Williams-Hemby, L, 1997
)
0.62

Toxicity

ExcerptReferenceRelevance
" The findings support earlier claims that anticholinergic medication has adverse effects on schizophrenic symptoms."( Adverse effects of anticholinergic medication on positive schizophrenic symptoms.
Bourne, RC; Crow, TJ; Ferrier, IN; Frith, CD; Gamble, SJ; Johnstone, EC; Owens, DG, 1983
)
0.27
" Adverse events related to movement disorders were reported in 3%."( Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004
)
0.32
" Changes in the scores, rates of symptom remission, and adverse effects were compared between the two groups."( Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.
Cao, Y; Chang, H; Fan, LL; Fang, DC; Lan, CH; Wu, ZL; Yu, YY, 2014
)
0.4
" The remission of symptoms (eructation, abdominal pain, anorexia, and other accompanying symptoms) in the combination group was significantly better than that in the monotherapy group, and no significant difference in the incidence of adverse events was observed between the two groups."( Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.
Cao, Y; Chang, H; Fan, LL; Fang, DC; Lan, CH; Wu, ZL; Yu, YY, 2014
)
0.4
" In addition, this combination treatment is safe, with a low incidence of adverse events."( Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders.
Cao, Y; Chang, H; Fan, LL; Fang, DC; Lan, CH; Wu, ZL; Yu, YY, 2014
)
0.4
" The other outcomes were the adverse events rate, HAMA/SAS score, and HAMD/SDS score."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.51
" Eleven RCTs reported adverse effects in both the PB plus FM and PB groups, there was no statistically significant difference in the adverse events rate between the 2 groups (n = 1207, OR = 2."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.51
"The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.51

Pharmacokinetics

ExcerptReferenceRelevance
" The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i."( Clinical pharmacokinetics of the depot antipsychotics.
Ereshefsky, L; Jann, MW; Saklad, SR,
)
0.13
" Moreover pharmacokinetic data increasingly have been clinically applied."( Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Knudsen, P, 1985
)
0.27
"Precise pharmacokinetic data of long-acting neuroleptics: apparent half life (T 1/2), time of peak plasma concentration (Tmax), bioavailability, has been a major contribution to determine optimal dosage of the drug."( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
Levron, JC; Ropert, R,
)
0.13
" The concentration of flupentixol dihydrochloride in plasma samples was analyzed by a developed validated LC-MS/MS assay method and the pharmacokinetic parameters of the established formulation were compared with the commercially available oral tablets."( Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride.
Abdelbary, A; Bendas, ER; Mostafa, DA; Ramadan, AA, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the safety and efficacy of Wuling Capsule combined with Deanxit in treating post-stroke depression (PSD)."( [Efficacy and safety of Deanxit combined with Wuling Capsule in treating post-stroke depression: a randomized controlled trial].
Fu, JL; Sun, XJ; Zhao, YW, 2008
)
0.35
" Patients in Wuling Capsule-treated group were administered with three Wuling Capsules three times a day, and patients in Deanxit-treated group were administered with Deanxit 10."( [Efficacy and safety of Deanxit combined with Wuling Capsule in treating post-stroke depression: a randomized controlled trial].
Fu, JL; Sun, XJ; Zhao, YW, 2008
)
0.35
" There were no significant side effects in Wuling Capsule-treated group, while the incidence of side effects was 9% in both groups administered with Deanxit."( [Efficacy and safety of Deanxit combined with Wuling Capsule in treating post-stroke depression: a randomized controlled trial].
Fu, JL; Sun, XJ; Zhao, YW, 2008
)
0.35
"A systematic literature search was conducted in 7 databases covering the period up to July 2018 to identify randomized controlled trials (RCTs) of PB combined with FM versus PB alone for IBS-D."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.51
"The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.51
" This study aims to analyze the effect of warming acupuncture and moxibustion at temples combined with Deanxit on tension headache."( Clinical observation of warming acupuncture and moxibustion at the temples combined with Deanxit in the treatment of tension headache with anxiety and depression: a retrospective study.
A, R; Bao, Q; Bo, A; Hu, R; Mu, R; Sa, R; Sai, YC; Te, M, 2021
)
0.62
"The use of warming acupuncture and moxibustion at temples combined with Deanxit in the treatment of tension headache significantly reduces the number and duration of headache attacks and decreases the degree of headache."( Clinical observation of warming acupuncture and moxibustion at the temples combined with Deanxit in the treatment of tension headache with anxiety and depression: a retrospective study.
A, R; Bao, Q; Bo, A; Hu, R; Mu, R; Sa, R; Sai, YC; Te, M, 2021
)
0.62
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" The absorption rate constant is slower than the elimination rate constant and therefore, the depot antipsychotics exhibit 'flip-flop' kinetics where the time to steady-state is a function of the absorption rate, and the concentration at steady-state is a function of the elimination rate."( Clinical pharmacokinetics of the depot antipsychotics.
Ereshefsky, L; Jann, MW; Saklad, SR,
)
0.13
" Optimal dose has been determined from the bioavailability of the oral formulation and the interval between two injections, it averages 15, 20 times the oral daily dose for haloperidol decanoate."( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
Levron, JC; Ropert, R,
)
0.13
" The bioavailability of orally administered cis(Z)-flupentixol was calculated to be about 40% with IV injection as reference."( Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate.
Andersen, J; Bjørndal, N; Dencker, SJ; Jørgensen, A; Lundin, L; Malm, U, 1982
)
0.26
" Depot neuroleptics also eliminate bioavailability problems related to absorption and first pass metabolism and give a stable plasma concentration."( Depot neuroleptics in relapse prevention: advantages and disadvantages.
Gerlach, J, 1995
)
0.29
"The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contributes to the poor bioavailability of many anticancer and antimicrobial agents as well as to drug resistance at the cellular level."( Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.
Dey, S; Hafkemeyer, P; Maki, N, 2003
)
0.32
"The human P-glycoprotein (Pgp, ABCB1) is an ATP-dependent efflux pump for structurally unrelated hydrophobic compounds, conferring simultaneous resistance to and restricting bioavailability of several anticancer and antimicrobial agents."( Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Chattopadhyay, A; Dey, S; Ghosh, P; Maki, N; Moitra, K; Silver, C, 2006
)
0.33
" Faster rate of absorption of flupentixol could be obtained from the oral film formulation and the relative bioavailability was found to be 151."( Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride.
Abdelbary, A; Bendas, ER; Mostafa, DA; Ramadan, AA, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sixty depressed outpatients were allocated to treatment with either amitriptyline (75-225 mg/day) or flupenthixol (1-5-4-5 mg/ day) in flexible dosage for six weeks. FlupenthIXol decanoate dosage was 20 mg every 2-3 weeks.

ExcerptRelevanceReference
" The dosage of drugs was varied according to clinical indications."( A comparative trial of the decanoates of flupenthixol and fluphenazine.
Card, IR; Hamilton, M; Mahmoud, MR; Wallis, GG, 1979
)
0.53
" The maximum/minimum fluctuation ratio indicates that dosage intervals longer than 2 weeks seem reasonable for most of the patients."( Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients.
Jøorgensen, A; Kirk, L; Stauning, JA, 1979
)
0.26
" Special attention is paid to pharmacokinetics, the methods for determining plasma concentration, to the profile of action and duration of action, to other dosage as well as to safety."( [Studies on the long acting neuroleptic agent flupenthixol decanoate--a review (author's transl)].
Sieberns, S, 1978
)
0.52
"Sixty depressed outpatients were allocated to treatment with either amitriptyline (75-225 mg/day) or flupenthixol (1-5-4-5 mg/day) in flexible dosage for six weeks under double-blind procedures."( A controlled comparison of flupenthixol and amitriptyline in depressed outpatients.
Hughes, WC; Lader, MH; Young, JP, 1976
)
0.77
" Stepwise titration of the drug resulted in an optimal daily dosage of 6 tablets (1 table, morning, 1 at noon, and 4 in the evening)."( The treatment of endomorphous and psychogenic depressions with a fixed combination of amitriptyline/flupenthixol (Lu 7410).
Grünberger, J; Saletu, B; Schanda, H, 1976
)
0.47
" Dosage was 1-3 mg daily."( Effect of flupenthixol on depression with special reference to combination use with tricyclic antidepressants. An uncontrolled pilot study with 45 patients.
Baba, O; Fujiwara, J; Hanaoka, M; Ishino, H; Sasaki, K, 1976
)
0.66
" The same dosage (in 70% of the patients from 40 to 80 mg) of penfluridol was used per week as was employed for flupenthixol decanoate per fortnight."( Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia.
Gerlach, J; Kramp, P; Kristjansen, P; Lauritsen, B; Lühdorf, K; Munkvad, I, 1975
)
0.68
" There was a negative correlation between the daily dosage of phenothiazine and the percentages of the polyunsaturated fatty acids arachidonic acid and alpha-linolenic acid+eicosapentaenoic acid+docosahexaenoic acid in thrombocytes (r = -0."( Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes.
Fischer, S; Kissling, W; Kuss, HJ, 1992
)
0.28
" Superfusion of the tissues with varying concentrations of 5-HT (10(-7) M to 10(-4) M) resulted in an inverted U-shaped dose-response curve, maximum alpha-MSH release being obtained with 10(-6) M 5-HT."( Regulation of alpha-melanocyte-stimulating hormone release from superfused slices of rat hypothalamus by serotonin and the interaction of serotonin with the dopaminergic system inhibiting peptide release.
Tiligada, E; Wilson, JF, 1989
)
0.28
" As in experiment 1, CCK produced "biphasic" dose-response effects with strong attenuation that persisted throughout the entire 60-min test at both high (1 microgram) and low (1 ng) doses."( CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
Ettenberg, A; Koob, GF; Weiss, F, 1989
)
0.28
"5 mg flupenthixol tablet in the morning and a placebo capsule at night (25 patients) or a 25 mg sustained-release amitriptyline capsule at night and a placebo tablet in the morning (26 patients), but at the end of the first or second weeks the dosage could be doubled according to the assessed clinical need."( Primary care treatment of depression in the elderly: a double-blind, multi-centre study of flupenthixol ('Fluanxol') and sustained-release amitriptyline.
Asskilt, O; Austad, SG; Fjellheim, J; Høstmaelingen, EA; Høstmaelingen, HJ; Kristiansen, PH; Ofsti, E; Olsen, TI; Skotte, T, 1989
)
1.01
" In these six cases it was demonstrated that the neuroleptics dosage was inappropriate, being either too high or too low as judged from the plasma concentrations."( [Quantitative approach to treatment with incisive neuroleptics by therapeutic monitoring].
Balant-Gorgia, AE; Eisele, R; Garrone, G, 1985
)
0.27
"Precise pharmacokinetic data of long-acting neuroleptics: apparent half life (T 1/2), time of peak plasma concentration (Tmax), bioavailability, has been a major contribution to determine optimal dosage of the drug."( [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
Levron, JC; Ropert, R,
)
0.13
" During the 44 week study the reduced dosage group showed increased morbidity and one-third of these patients had a schizophrenic relapse."( The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime.
Cookson, IB, 1987
)
0.54
" Blood samples were taken 7 days after each injection and on the last day of the dosage interval."( Radioreceptor assay in checking serum concentration in long-term treatment with cis(z)-flupenthixol decanoate.
Lipska, B; Nurowska, K; Szukalski, B; Welbel, L, 1987
)
0.5
" Experimental factors were dosage (0, 1 and 2 mg flupentixol/day), time of measurement (before, during, and after 4 days of treatment), and the trait variable "neuroticism" (high vs."( [Subjective findings in emotionally stable and labile subjects following oral application of flupenthixol in small doses].
Manzey, D; Rösler, F; Stieglitz, RD, 1986
)
0.49
" It was concluded that 4-week intramuscular administration of haloperidol decanoate provides appropriate control of schizophrenic symptoms, but that flupenthixol decanoate should be dosed at shorter intervals."( Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison.
Eberhard, G; Hellbom, E, 1986
)
0.77
" In the presence of spiroperidol, the Hill coefficients determined from dose-response curves of the inhibition of the binding of [alpha-3H]flupenthixol by antagonists or by agonists in the presence of GTP suggest that the binding reaction obeys simple Michaelis-Menten kinetics for a single class of binding sites."( Assay of dopamine receptors with [alpha-3H]flupenthixol.
Huff, RM; Molinoff, PB, 1985
)
0.73
" Reliable drug effects were observed with a dosage of 2 mg/day after 4 days of treatment."( Delineation of pharmacopsychological effects by means of endogenous event-related brain potentials: an exemplification with flupentixol.
Manzey, D; Rösler, F; Sojka, B; Stieglitz, RD, 1985
)
0.27
" The dose-response curves showed potencies similar to those in several animal behavioral paradigms."( Electrophysiologic interactions of antipsychotic drugs with central noradrenergic pathways.
Freedman, R; Geller, HM; Hoffer, BJ; Marwaha, J, 1981
)
0.26
"In a series of 36 patients with acute schizophrenia flupenthixol dosage was blindly adjusted to give a fixed level of sedation."( Adverse effects of anticholinergic medication on positive schizophrenic symptoms.
Bourne, RC; Crow, TJ; Ferrier, IN; Frith, CD; Gamble, SJ; Johnstone, EC; Owens, DG, 1983
)
0.52
"Serum concentrations of cis(Z)-flupentixol have been measured in patients on cis(Z)-flupentixol decanoate injections during successive dosage intervals of 2-4 weeks."( Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo.
Jørgensen, A; Saikia, JK, 1983
)
0.27
" Mean daily dosage was approximately 112 mg flupenthixol and 18 mg haloperidol."( Flupenthixol versus haloperidol in acute psychosis.
Parent, M; Toussaint, C, 1983
)
1.97
"Serum concentrations of clopenthixol and flupenthixol have been determined during a four weeks dosage interval in patients treated with intramuscular injections of clopenthixol decanoate or flupenthixol palmitate in Viscoleo."( Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels.
Jrgensen, A; Overø, KF, 1980
)
0.87
" the minimum serum concentration in the dosage interval and the sera under the serum concentration curve have been correlated to 14 parameters for clinical outcome, viz."( Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome.
Dencker, SJ; Jørgensen, A; Malm, U; Overø, KF, 1980
)
0.6
"Sixty-eight depressed out-patients were allocated to treatment with either oral amitriptyline (75-225 mg/day) or intramuscular flupenthixol decanoate (10-30 mg every 14 days) in flexible dosage for 12 weeks under double-blind procedures."( A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients.
John, G; Lader, MH; Tam, W; Young, JP, 1982
)
0.77
" The flupenthixol decanoate dosage was 20 mg every 2-3 weeks."( Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium.
Aaskoven, O; Ahlfors, UG; Baastrup, PC; Dencker, SJ; Elgen, K; Lingjaerde, O; Pedersen, V; Schou, M, 1981
)
2.22
" 2 Inhibition of responses to adrenaline and noradrenaline was non-competitive, since the maxima and slopes of dose-response curves of these agonists were reduced."( alpha-Flupenthixol: an antagonist of dopamine-evoked fluid secretion by an insect salivary gland preparation.
Breward, J; House, CR; Smith, RK, 1980
)
0.74
"Doctors' prescription and dosing behaviour was investigated using data from 9 clinical trials in 550 patients treated with psychotropics."( Correct titration of non-drugs and some other methodological issues.
Beneke, M; Fritze, J; Rasmus, W; Rød, IS, 1994
)
0.29
" All five ritanserin-treated subjects followed the same dosing regimen."( Serotonin-2 and dopamine-1 binding components of clozapine in frontal cortex and striatum in the human brain visualized by positron emission tomography.
Agren, H; Antoni, G; Fasth, KJ; Hartvig, P; Långström, B; Lindström, L; Lundberg, T; Lundqvist, H; Reibring, L, 1996
)
0.29
"There are no data available on the risk of extrapyramidal symptoms when using long-term flupenthixol in low dosage in patients suffering from anxiety and depressive disorders."( Tolerability of low dose neuroleptics: a case control study of flupenthixol.
Fritze, J; Spreda, I, 1997
)
0.76
" Extrapyramidal tolerability was better in the ASP group, as demonstrated by smaller increases in the Simpson-Angus Scale, the AIMS, and the Barnes Akathisia Scale in ANCOVA analyses with dosage as covariate."( Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
Adler, G; Benkert, O; Gattaz, WF; Gründer, G; Hillert, A; Philipp, M; Rein, W; Sauer, H; Schröder, J; Wetzel, H, 1998
)
0.3
" Future studies should focus on dosing issues, the differentiation between short- and long-term effects and the identification of subgroups of patients with particular psychopathology."( Flupenthixol as a potential pharmacotreatment of alcohol and cocaine abuse/dependence.
De Vry, J; Soyka, M, 2000
)
1.75
" The method was successfully applied to the determination of these compounds in dosage forms and biological fluids."( Flow-injection chemiluminometric determination of some thioxanthene derivatives in pharmaceutical formulations and biological fluids using the [Ru(dipy)3(2+)]-Ce(IV) system.
al-Tamimi, SA; Alwarthan, AA; Aly, FA, 2001
)
0.31
" Analyses of CFA-derived factor scores showed that ASP was significantly superior to FPX regarding the latent 'depressive' dimension, independent of baseline scores, dosage and changes in akinesia."( Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis.
Benkert, O; Müller, MJ; Wetzel, H, 2002
)
0.31
" Changes in circulating retinol with time for chronic dosing showed drug treatment (P<0."( Flupenthixol and cefotiam: effects on vitamin A metabolism in rats.
Fielenbach, T; Rave, G; Schindler, R, 2004
)
1.77
" Therefore, if flupentixol's efficacy on negative symptoms is based on its interaction with 5-HT(2A) and/or D(1) receptors, it should be highly dependent on serum concentration and thus on dosage and metabolism."( Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Bares, R; Bartels, M; Beneke, M; Glaser, T; Machulla, HJ; Noda, S; Reimold, M; Schaefer, JE; Solbach, C; Wormstall, H, 2007
)
0.34
" A dose-response curve of chronic treatment with the non-selective dopaminergic antagonist cis-flupenthixol was determined in the ABA model."( Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa.
Adan, RA; Hillebrand, JJ; Luijendijk, MC; Verhagen, LA, 2009
)
0.57
" Intra-DLS infusion of the dopamine receptor antagonist α-flupenthixol did not affect the acquisition of cocaine self-administration, increased cocaine self-administration under a fixed ratio-1 (FR-1) schedule of reinforcement, caused a rightward and downward shift of the dose-response curve of cocaine under an FR-1 schedule of reinforcement and decreased responding for cocaine under a progressive ratio (PR) schedule of reinforcement."( Distinct contributions of dopamine in the dorsolateral striatum and nucleus accumbens shell to the reinforcing properties of cocaine.
Broekhoven, MH; Damsteegt, R; Vanderschuren, LJ; Veeneman, MM, 2012
)
0.62
"01 for the differences) in dose-response studies."( Intrathecal chlorprothixene, cis(z)-flupenthixol, chlorpromazine and fluphenazine for prolonged spinal blockades of sensory and motor functions in rats.
Chen, YC; Chen, YW; Chu, CC; Leung, YM; Wang, JJ, 2012
)
0.65
"Many pharmaceuticals include highly potent active pharmaceutical ingredients (API), which only require a small dosage to obtain the desired therapeutic effect."( Fluorescence spectroscopy in process analytical technology (PAT): simultaneous quantification of two active pharmaceutical ingredients in a tablet formulation.
Allesø, M; Engelsen, SB; Rinnan, Å; Warnecke, S, 2015
)
0.42
" Aripiprazole produced a U-shaped dose-response curve on MK-801-induced bar pressing behavior, a dose-dependent decrease in locomotor activity but no changes in IL pERK1/2 labeling."( Attenuation of MK-801-induced behavioral perseveration by typical and atypical antipsychotic pretreatment in rats.
Holahan, MR; Stocco, MR; Tuplin, EW, 2015
)
0.42
" Treatment success rates at 6 months were extracted or extrapolated from the studies and plotted against dose to estimate a dose-response curve."( Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature.
Bailey, L; Taylor, D, 2019
)
0.51
"Data from 16 studies (n = 514) allowed estimation of a dose-response curve which rises steeply between the chosen placebo anchor (25% success rate) and 10 mg every 2 weeks before reaching a maximum between 20 and 40 mg every 2 weeks (80-95% success rates)."( Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature.
Bailey, L; Taylor, D, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
dopaminergic antagonistA drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
thioxanthenesThioxanthene and its substitution derivatives.
flupenthixolA thioxanthene derivative having a trifluoromethyl substituent at the 2-position and a 3-(4-(2-hydroxyethyl)piperazin-1-yl)propylidene group at the 10-position with undefined double bond stereochemistry.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (81)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
acetylcholinesteraseHomo sapiens (human)Potency17.37680.002541.796015,848.9004AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency2.90930.01846.806014.1254AID624148
phosphopantetheinyl transferaseBacillus subtilisPotency7.94330.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency30.10653.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.60320.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency26.09040.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency48.56760.031637.5844354.8130AID504865; AID540327
TDP1 proteinHomo sapiens (human)Potency18.02490.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency10.07550.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency25.38400.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.49150.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency13.93510.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency22.09510.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.68520.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.29580.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency29.30520.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.21080.000229.305416,493.5996AID743069; AID743079
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency6.91780.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
glucocerebrosidaseHomo sapiens (human)Potency20.48390.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency17.14920.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency25.82220.001019.414170.9645AID743140
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency21.19230.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency46.45150.016525.307841.3999AID602332
thyroid stimulating hormone receptorHomo sapiens (human)Potency33.49150.001628.015177.1139AID1259395
activating transcription factor 6Homo sapiens (human)Potency27.90280.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency26.832519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency16.45120.057821.109761.2679AID1159526; AID1159528
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
D(1A) dopamine receptorHomo sapiens (human)Potency0.08510.02245.944922.3872AID488982; AID488983
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency72.33420.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency35.48130.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency2.81840.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency10.84580.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency19.09750.00378.618923.2809AID2660; AID2666; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.04500.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency28.93420.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency30.05340.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency29.93490.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency21.19230.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency17.78280.891312.067628.1838AID1487
Interferon betaHomo sapiens (human)Potency26.88680.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency13.33050.009610.525035.4813AID1479145; AID1479148
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency33.49150.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency25.63720.011912.222168.7989AID588378; AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)89.50000.21005.553710.0000AID386625
Ubiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)IC50 (µMol)7.00002.00005.61258.0000AID1315765
Potassium channel subfamily K member 2Homo sapiens (human)IC50 (µMol)2.00000.40003.92279.0000AID1307728
DRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00030.50267.7625AID218770
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00030.39075.4000AID218770
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00030.35635.4000AID218770
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00030.38715.4000AID218770
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)89.50002.03005.53139.9000AID386625
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00300.00010.54948.4000AID218770
WD repeat-containing protein 48Homo sapiens (human)IC50 (µMol)7.00002.00006.31678.0000AID1315765
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.00220.00030.70285.3660AID203852
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.00090.00010.40364.8000AID88008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (249)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
skeletal system developmentUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
DNA repairUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
regulation of DNA repairUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
response to UVUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
positive regulation of error-prone translesion synthesisUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
DNA damage responseWD repeat-containing protein 48Homo sapiens (human)
spermatogenesisWD repeat-containing protein 48Homo sapiens (human)
single fertilizationWD repeat-containing protein 48Homo sapiens (human)
multicellular organism growthWD repeat-containing protein 48Homo sapiens (human)
skin developmentWD repeat-containing protein 48Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATWD repeat-containing protein 48Homo sapiens (human)
embryonic organ developmentWD repeat-containing protein 48Homo sapiens (human)
skeletal system morphogenesisWD repeat-containing protein 48Homo sapiens (human)
homeostasis of number of cellsWD repeat-containing protein 48Homo sapiens (human)
positive regulation of epithelial cell proliferationWD repeat-containing protein 48Homo sapiens (human)
seminiferous tubule developmentWD repeat-containing protein 48Homo sapiens (human)
regulation of protein monoubiquitinationWD repeat-containing protein 48Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationWD repeat-containing protein 48Homo sapiens (human)
double-strand break repair via homologous recombinationWD repeat-containing protein 48Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (82)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
peptidase activityUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingWD repeat-containing protein 48Homo sapiens (human)
double-stranded DNA bindingWD repeat-containing protein 48Homo sapiens (human)
single-stranded DNA bindingWD repeat-containing protein 48Homo sapiens (human)
protein bindingWD repeat-containing protein 48Homo sapiens (human)
deubiquitinase activator activityWD repeat-containing protein 48Homo sapiens (human)
ubiquitin bindingWD repeat-containing protein 48Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (64)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 1Homo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytoplasmWD repeat-containing protein 48Homo sapiens (human)
nucleusWD repeat-containing protein 48Homo sapiens (human)
nucleoplasmWD repeat-containing protein 48Homo sapiens (human)
lysosomeWD repeat-containing protein 48Homo sapiens (human)
late endosomeWD repeat-containing protein 48Homo sapiens (human)
cytosolWD repeat-containing protein 48Homo sapiens (human)
intracellular membrane-bounded organelleWD repeat-containing protein 48Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID554098Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry after 5 mins2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1315765Inhibition of human USP1/UAF1 complex using Ub-Rho as substrate by qHTS assay2016Journal of medicinal chemistry, Oct-27, Volume: 59, Issue:20
Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID176355Compound was tested orally (po) in rats for its ability to induce catalepsy, an effect normally related to clinical extrapyramidal side effects;value ranges from 1.3-3.41983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID171955compound was evaluated for its ability to produce catalepsy activity in rats; Dose administered perorally is 2.5 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID521209Antiproliferative activity against mouse astrocyte cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID63368In vivo binding affinity against dopamine (D1) receptor in rat caudate-putamen tissue using [3H]SCH-23390 as radioligand2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and affinity of a possible byproduct of electrophilic radiolabeling of [123I]IBZM.
AID169959Compound was assessed for its ability to produce catalepsy in rats; Dose administered perorally is 2.5 mg/kg; Group score is 31-401980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID521210Ratio of EC50 for mouse astrocytes to EC50 for mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID521214Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID88008Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID169813Compound was assessed for its ability to block a conditioned avoidance response; Dose administered perorally is 2.5 mg/kg; 31-50%block1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID593483Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells at 4 times IC50 for 5 mins measured after 60 mins by topcount scintillation counting2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Molecular properties affecting fast dissociation from the D2 receptor.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID103232Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID170119Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 2.5 mg/kg; 31-50% block1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID176352Compound was tested orally (po) in rats for antagonism of stereotypies induced by amphetamine; value ranges from 2.5-4.71983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
AID218770Ability to displace [3H]haloperidol from rat striatal membranes, in order to measure its intrinsic affinity for the dopamine (DA) receptor1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
AID1307728Inhibition of of human TREK1 expressed in whole COS cells assessed as reduction in channel currents2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID134417Lethal dose in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID130391Hypothermia in mice after peroral administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID521215Antiproliferative activity against mouse neural precursor cells by colony formation assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID112708Hypothermia in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID114482Compound (administered intraperitoneally) was assessed for neuroleptic activity to antagonize methyl phenidate induced stereotypes in mice1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID116898Lethal dose in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID521208Antiproliferative activity against mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1345833Human D3 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1345718Human D1 receptor (Dopamine receptors)1994The Journal of biological chemistry, Nov-11, Volume: 269, Issue:45
High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345788Human D2 receptor (Dopamine receptors)1994The Journal of pharmacology and experimental therapeutics, Jan, Volume: 268, Issue:1
Expression and pharmacological characterization of the human D3 dopamine receptor.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (919)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990425 (46.25)18.7374
1990's183 (19.91)18.2507
2000's141 (15.34)29.6817
2010's145 (15.78)24.3611
2020's25 (2.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.94 (24.57)
Research Supply Index6.96 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index133.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials128 (13.78%)5.53%
Trials0 (0.00%)5.53%
Reviews32 (3.44%)6.00%
Reviews2 (5.26%)6.00%
Case Studies85 (9.15%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (0.22%)0.25%
Observational0 (0.00%)0.25%
Other682 (73.41%)84.16%
Other36 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors [NCT03205228]Phase 340 participants (Actual)Interventional2017-07-07Completed
Interventional, Open-label, Randomised, Crossover, Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations - Film Coated Tablet (Test Treatment) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) and Coated Tablet (Flu [NCT02660840]Phase 184 participants (Actual)Interventional2016-01-31Completed
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia [NCT01164059]Phase 4149 participants (Actual)Interventional2010-02-28Completed
Interventional, Single Dose, Open-label, Randomised, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) [NCT02179931]Phase 130 participants (Actual)Interventional2014-06-30Completed
Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients [NCT04898270]Phase 430 participants (Actual)Interventional2019-12-19Completed
Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data [NCT02582736]725,489 participants (Actual)Observational2012-04-30Completed
Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia: A Randomized Comparison of Different Prescribing Behaviors [NCT01851863]Phase 4262 participants (Actual)Interventional2013-05-31Completed
Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics [NCT00000274]Phase 260 participants Interventional1997-03-31Completed
Flupenthixol Treatment in Schizophrenic Cocaine Abusers [NCT00000266]Phase 20 participants Interventional1994-08-31Completed
Flupenthixol Decanoate in Methamphetamine Smoking [NCT00000241]Phase 258 participants Interventional1994-02-28Completed
Infusion Laboratory: Protocol 5 (Flupenthixol) [NCT00000349]Phase 10 participants InterventionalActive, not recruiting
Cocaine Abuse and ADHD [NCT00000275]Phase 216 participants Interventional1996-11-30Completed
Clinical Study of Flupentixol and Melitracen Tablets in the Treatment of Non Random Emotional Disorder [NCT04970667]Phase 4100 participants (Actual)Interventional2018-01-01Completed
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Interventional, Randomized, Single Dose, Open-label, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) - in Fasted and Fed Conditions [NCT03472651]Phase 160 participants (Actual)Interventional2018-05-07Completed
Short-term and Low-dose Application of Neuromodulators Increases Treatment Efficacy and Minimizes Antidepressant Discontinuation Syndrome in Refractory Functional Dyspepsia [NCT05099913]220 participants (Anticipated)Interventional2020-08-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01851863 (4) [back to overview]Change From Baseline in Dyspepsia Symptom Questionnaire at Week 8
NCT01851863 (4) [back to overview]Compliance of Flupentixol-Melitracen
NCT01851863 (4) [back to overview]Number of Participants With Adverse Reaction
NCT01851863 (4) [back to overview]Change From Baseline in Psychiatric Symptom on Hospital Anxiety and Depression Scale at Week 8

Change From Baseline in Dyspepsia Symptom Questionnaire at Week 8

The severity of patients' dyspeptic symptoms were assessed using the Leeds Dyspepsia Questionnaire (LDQ) at week 0 and 8. The LDQ contains eight items about epigastric pain, retro-sternal pain, regurgitation, nausea, vomiting, belching, early satiety and dysphagia with six grades for each item and a sum of the eight symptom scores make the LDQ score.LDQ scores of 0 - 4 were classified as very mild dyspepsia, 4 - 8 as mild dyspepsia, 9 -15 as moderate dyspepsia, and > 15 as severe or very severe dyspepsia. The change of LDQ scores was calculated by LDQ scores of 8 weeks minus baseline, with lower values represent a better outcome. (NCT01851863)
Timeframe: week 0 and 8

Interventionunits on LDQ scale (Mean)
Deanxit(Psychological and GI) + Omeprazole-3.85
Deanxit(Psychological) + Omeprazole-2.51
Deanxit(Without Explanation) + Omeprazole-2.49
Proton Pump Inhibitor-1.31

[back to top]

Compliance of Flupentixol-Melitracen

The patients were asked to keep a diary to record their medication intake. At each visit (weeks 1, 2, 4, 8), the patient bring back the drug bottle and the diary, then the physician recorded the number of pills remaining in the bottle. Pills remained more than 20% at any visit or seven days of consecutive abstinence were adopted as the criterion for identifying therapy noncompliance. (NCT01851863)
Timeframe: weeks 1, 2, 4, 8

Interventionparticipants (Number)
Deanxit(Psychological and GI) + Omeprazole44
Deanxit(Psychological) + Omeprazole28
Deanxit(Without Explanation) + Omeprazole31

[back to top]

Number of Participants With Adverse Reaction

Number of participants with adverse reactions were recorded to analyze the safety profile of treatment. (NCT01851863)
Timeframe: 8 weeks

Interventionparticipants (Number)
Deanxit(Psychological and GI) + Omeprazole6
Deanxit(Psychological) + Omeprazole9
Deanxit(Without Explanation) + Omeprazole5
Proton Pump Inhibitor2

[back to top]

Change From Baseline in Psychiatric Symptom on Hospital Anxiety and Depression Scale at Week 8

Each patient was surveyed using the Hospital Anxiety and Depression Scale to assess the psychiatric symptom at week 0 and 8.The HADS consists of 14 items, seven of which assess anxiety, and seven assess depression. The anxiety and depression subscales were calculated independently. The patients were asked to answer each item on a four-point (0 - 3) scale. Scores of 0 to 7 on either subscale can be regarded as within the normal range, scores of 8 to 10 are suggestive of the presence of the respective state, and scores of 11 or higher indicate the probable presence of the respective mood disorder. The change of HADS scores was calculated by HADS anxiety and depression scores of 8 weeks minus baseline, with lower values indicate better outcome. (NCT01851863)
Timeframe: week 0 and 8

,,,
Interventionunits on HADS score (Mean)
HADS anxiety scoreHADS depression score
Deanxit(Psychological and GI) + Omeprazole-4.46-4.82
Deanxit(Psychological) + Omeprazole-2.29-2.25
Deanxit(Without Explanation) + Omeprazole-2.78-2.86
Proton Pump Inhibitor-1.68-1.88

[back to top]